Korean J Med.
2001 Feb;60(2):167-174.
Selective bowel decontamination for the prevention of infection in acute myelogenous leukemia: A prospective randomized trial
- Affiliations
-
- 1Department of Internal Medicine, The Catholic University of Korea, Seoul, Korea.
Abstract
-
BACKGROUND: Infections are still a frequent cause of morbidity and mortality in patients with hematologic malignancies. Antimicrobial prophylaxis in neutropenic patients has been practised for several decades. But, recently the rates of occurrence for pathogens have significantly changed (from predominance of gram-negative to gram-positive species) under selective pressure of antimicrobial prophylaxis, and novel resistance mechanisms have emerged. We investigated this study to assess the effectiveness of selective bowel decontamination for preventing infections in granulocytopenic patients who are receiving chemotherapy for acute myelogenous leukemia.
METHODS
In a prospective, randomized trial, we evaluated the efficacy of oral ciprofloxacin (250 mg p.o.
twice a day), roxithromycin (150 mg p.o. twice a day), fluconazole (50 mg p.o.) in 95 adult patients with
acute myelogenous leukemia who undergone intensive chemotherapy. Prophylaxis was begun within 72
hours of initiation of the chemotherapy and continued until the onset of fever, signs or symptoms of
infection, serious adverse effect, or recovery of the leukocyte count to > or = 1,000/mm3.
RESULTS
46 decontamination regimen treated patients and 49 control patients were assessable for
efficacy. No difference was noted between the two groups in occurrence of fever during neutropenia, time
to onset of first fever, sites of infection, duration of using systemic antimicrobials, overall infection rates,
infection-related mortality, or hospitalization day. Decontamination regimen reduced the gram-negative
infections, but increased the gram-positive infections. Among those who received decontamination regimen,
the incidence of resistance to ciprofloxacin was 100% for gram-negative species. And resistance to
erythromycin for gram-positive species, irrespective of decontamination, was very much high (90-100%).
CONCLUSION
The approach of selective decontamination has not led to fewer febrile episodes or to a
lower mortality in neutropenia after chemotherapy for acute myelogenous leukemia. It should be considered
that we had better not prescribe decontamination regimen because of increment of infection due to
gram-positive species and high resistance rate to fluoroquinolone and macrolide. Additional trials are needed
to establish the efficacy of decontamination for other malignancies, aplastic anemia, or bone marrow
transplantation.